RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Pacira Biosciences Stock

Pacira Biosciences ROE 2024

Pacira Biosciences ROE

0.05

Ticker

PCRX

ISIN

US6951271005

WKN

A1H68T

In 2024, Pacira Biosciences's return on equity (ROE) was 0.05, a 135.02% increase from the 0.02 ROE in the previous year.

Pacira Biosciences Aktienanalyse

What does Pacira Biosciences do?

Pacira Biosciences Inc. is an international pharmaceutical company specializing in the development and manufacture of innovative drugs for use in anesthesia, pain management, and oncology. The company was founded in 2007 and is headquartered in Parsippany, New Jersey. Pacira Biosciences' success story began with the development of EXPAREL, a long-acting painkiller based on liposome technology. EXPAREL was the first product approved by the US Food and Drug Administration (FDA) for local infiltration to relieve pain after surgery. Since then, the company has expanded its portfolio and now offers products for use in oncology and other areas of medicine. Pacira Biosciences' business model is based on the manufacture and sale of high-quality, innovative drugs both in the US and internationally. Product development is done in close collaboration with doctors and patients to ensure that patient needs are met and medical requirements are fulfilled. The company operates in three main divisions: anesthesia, pain management, and oncology. In the anesthesia division, Pacira Biosciences offers the product EXPAREL, which is used for local infiltration into the surgical wound to relieve pain after surgery. EXPAREL is a liposomal, slow-release painkiller that enables patients to recover without pain and minimizes the risk of opioid dependence. In the pain management division, Pacira Biosciences has developed the products bupivacaine and meloxicam, which are used in the treatment of acute and chronic pain. These products provide a safe and effective alternative to opioids for pain management. In the oncology division, the company has introduced the product ONIVYDE, which is used for the treatment of patients with metastatic pancreatic cancer. ONIVYDE was developed in collaboration with the FDA and has proven to be effective in combating cancer. In addition to offering products, Pacira Biosciences works closely with doctors, hospitals, and government agencies to ensure that the products are used safely and effectively. The company also conducts extensive research and development activities to develop new products and improve existing ones. In conclusion, Pacira Biosciences Inc. is a leading international company specializing in innovative pharmaceuticals in the fields of anesthesia, pain management, and oncology. The company is actively working on developing new innovative products and offering doctors and patients a safe and effective alternative to traditional pain medications. With its strong commitment to the healthcare industry, Expard will continue to advance the development of new and therapeutic agents to better assist patients. Answer: Pacira Biosciences Inc. is an international pharmaceutical company specializing in the development and manufacture of innovative drugs for anesthesia, pain management, and oncology. They are known for their product EXPAREL, a long-acting painkiller approved by the FDA for local infiltration after surgery. The company operates in three divisions and works closely with healthcare professionals and government agencies to ensure safe and effective use of their products. They are committed to advancing healthcare through research and development. Pacira Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Pacira Biosciences's Return on Equity (ROE)

Pacira Biosciences's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Pacira Biosciences's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Pacira Biosciences's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Pacira Biosciences’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Pacira Biosciences stock

What is the ROE (Return on Equity) of Pacira Biosciences this year?

The ROE of Pacira Biosciences this year is 0.05 undefined.

How has the Return on Equity (ROE) of Pacira Biosciences developed compared to the previous year?

The ROE of Pacira Biosciences has increased by 135.02% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Pacira Biosciences?

A high ROE indicates that Pacira Biosciences generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Pacira Biosciences?

A low ROE can indicate that Pacira Biosciences is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Pacira Biosciences affect the company?

A change in ROE (Return on Equity) of Pacira Biosciences can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Pacira Biosciences?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Pacira Biosciences?

Some factors that can influence Pacira Biosciences's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Pacira Biosciences pay?

Over the past 12 months, Pacira Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pacira Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Pacira Biosciences?

The current dividend yield of Pacira Biosciences is .

When does Pacira Biosciences pay dividends?

Pacira Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pacira Biosciences?

Pacira Biosciences paid dividends every year for the past 0 years.

What is the dividend of Pacira Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pacira Biosciences located?

Pacira Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pacira Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pacira Biosciences from 11/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/12/2024.

When did Pacira Biosciences pay the last dividend?

The last dividend was paid out on 11/12/2024.

What was the dividend of Pacira Biosciences in the year 2023?

In the year 2023, Pacira Biosciences distributed 0 USD as dividends.

In which currency does Pacira Biosciences pay out the dividend?

The dividends of Pacira Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Pacira Biosciences

Our stock analysis for Pacira Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pacira Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.